Excess mortality in Northeast Iran caused by COVID-19: Neglect of offset community transformations of health

Abstract

Objective: To make evidence-based decisions based on broad mortality trends for Razavi Khorasan province, Iran. Methods: In order to determine the baseline number of deaths, we used univariate time series analyses for monthly data from the monthly vital statistics reports (From April 2015 to March 2022). For excess mortalities, these baselines were subtracted from reported deaths with a 95% prediction interval. To compare time and causes, a P-score was calculated. Results: From March 2020 to March 2022, there were 61 949 registered deaths, and the estimated deaths with a 95% confidence interval (CI) were 43 246.16 (35 718.28, 50 774.05). So, in 2020-2021 and 2021-2022, the death counts were 35.15% and 51.33% higher than projected. A total of 18 666 cardiovascular diseases were reported and a total of 15 704.46 (12 006.95, 19 401.96) was estimated. The P-score for this duration was 14.49% and 23.23% higher than expected. Infectious and parasitic diseases plus COVID-19 were 16 633 and estimated to be 1 044.87 (456.77, 1 632.96). A total of 4 420 diseases of the respiratory system were reported, and 4 564.94 deaths were predicted (2 277.43, 6 852.43). In the first year of the pandemic, the P-score dropped to -35.28% and in the second year, it jumped sharply to 22.38%. Conclusions: Excess mortality, along with cause-specific mortality, can be helpful for monitoring trends and developing public health policies at the local, national, and international levels.

Keywords

Mortality / COVID-19 / Health Systems Plans / Prediction / Cardiovascular deaths

References

[1] Danaei G, Farzadfar F, Kelishadi R, Rashidian A, Rouhani OM, Ahmadnia S, et al. Iran in transition. Lancet 2019; 393(10184):1984-2005.

[2] Farzadfar F, Naghavi M, Sepanlou SG, Moghaddam SS, Dangel WJ, Weaver ND, et al. Health system performance in Iran: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2022; 399(10335):1625-1645.

[3] Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396(10258):1204-1222.

[4] Aminorroaya A, Fattahi N, Azadnajafabad S, Mohammadi E, Jamshidi K, Rouhifard Khalilabad M, et al. Burden of non-communicable diseases in Iran: Past, present, and future. J Diabetes Metab 2020; 19:1027-1036.

[5] Azadnajafabad S, Mohammadi E, Aminorroaya A, Fattahi N, Rezaei S, Haghshenas R, et al. Non-communicable diseases’ risk factors in Iran; A review of the present status and action plans. J Diabetes Metab Disord 2021. doi: 10.1007/s40200-020-00709-8.

[6] Sajadi HS, Ehsani-Chimeh E, Majdzadeh R. Universal health coverage in Iran: Where we stand and how we can move forward. MJIRI 2019; 33:9.

[7] Karlinsky A, Kobak D. Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset. Elife 2021; 10:e69336.

[8] Esmaeilzadeh N, Shakeri M, Esmaeilzadeh M, Rahmanian V. ARIMA models forecasting the SARS-CoV-2 in the Islamic Republic of Iran. Asian Pac J Trop Med 2020; 13(11):521-524.

[9] Esmaeilzadeh N, Bahonar A, Foroushani AR, Nasehi M, Amiri K, Hadjzadeh MA. Temporal trends and prediction of bovine tuberculosis: A time series analysis in the North-East of Iran. Iran J Vet Res 2022; 23(1):12.

[10] von Cube M, Timsit JF, Kammerlander A, Schumacher M. Quantifying and communicating the burden of COVID-19. BMC Med Res Methodol 2021; 21(1):1.

[11] Abdollahzadeh H, Rahmanian V, Sharifi N, Zahedi R, Bajestani MJ, GholianAval M, et al. Risks assessment of adherence to non-pharmaceutical measures towards COVID-19 among residents of Mashhad in the North-East of Iran during the awful wave of the epidemic. Fam Med Prim 2021; 10(9):3211.

[12] Bassi LL. Allocating COVID-19 vaccines globally: An urgent need. JAMA Health Forum 2021; 2(2):e210105.

[13] Sinnathamby MA, Whitaker H, Coughlan L, Bernal JL, Ramsay M, Andrews N. All-cause excess mortality observed by age group and regions in the first wave of the COVID-19 pandemic in England. Euro Surveill 2020; 25(28):2001239.

[14] Flahault A. COVID-19 case profile is changing with the vaccine. Anaesth Crit Care Pain Med 2021; 40(2):100851.

[15] Nielsen J, Nørgaard SK, Lanzieri G, Vestergaard LS, Moelbak K. Sex-differences in COVID-19 associated excess mortality is not exceptional for the COVID-19 pandemic. Sci Rep 2021; 11(1):1-9.

[16] De Rosa S, Spaccarotella C, Basso C, Calabro MP, Curcio A, Filardi PP, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J 2020; 41(22):2083-2088.

[17] Čulić V, AlTurki A, Proietti R. COVID-19 pandemic and possible rebound phenomenon in incidence of acute myocardial infarction. Can J Cardiol 2021; 37(8):1294.

[18] De Filippo O, D’Ascenzo F, Angelini F, Bocchino PP, Conrotto F, Saglietto A, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. NEJM 2020; 383(1):88-89.

[19] Rattka M, Dreyhaupt J, Winsauer C, Stuhler L, Baumhardt M, Thiessen K, et al. Effect of the COVID-19 pandemic on mortality of patients with STEMI: A systematic review and meta-analysis. Heart 2021; 107(6):482-487.

[20] Mayol J, Artucio C, Batista I, Puentes A, Villegas J, Quizpe R, et al. An international survey in Latin America on the practice of interventional cardiology during the COVID-19 pandemic, with a particular focus on myocardial infarction. Neth Heart J 2020; 28(7):424-430.

[21] Ioannidis JP. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. Eur J Clin Invest 2020; 50(12):e13423.

[22] Sinnathamby MA, Whitaker H, Coughlan L, Bernal JL, Ramsay M, Andrews N. All-cause excess mortality observed by age group and regions in the first wave of the COVID-19 pandemic in England. Euro Surveill 2020; 25(28):2001239.

[23] Rodriguez-Gonzalez M, Castellano-Martinez A, Cascales-Poyatos HM, Perez-Reviriego AA. Cardiovascular impact of COVID-19 with a focus on children: A systematic review. World J Clin Cases 2020; 8(21):5250.